{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:24:27Z","timestamp":1760909067065},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T00:00:00Z","timestamp":1494288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Male breast cancer (MBC) as a second primary cancer (SPC) has a known association with prior MBC. However, its association with non-breast index malignancies, relative to population risk, has not been previously reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>Using Surveillance, Epidemiology, and End Results program (9 catchment area) data, we identified MBCs diagnosed from 1973\u20132012 as their SPC. Information regarding the index malignancy was also obtained. Standardized incidence ratios (SIR) of MBC as SPC were estimated, along with incidence rates and trends. Kaplan-Meier curves were used to estimate survival.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Over a 38-year period, 464 MBCs were identified as SPC. The most common index malignancies were breast (SIR 30.86, 95% confidence interval [CI] 21.50\u201342.92, p\u2009&amp;lt;\u2009.001), lymphoma (SIR 1.58, 95% CI 1.08\u20132.22, p\u2009=\u2009.014), melanoma (SIR 1.26, 95% CI 0.80\u20131.89), urinary (SIR 1.05, 95% CI 0.74\u20131.43), colorectal (SIR 0.94, 95% CI 0.69\u20131.24), and prostate (SIR 0.93 95% CI 0.81\u20131.07). Apart from the known association with prior breast cancer, the only significant association was with lymphoma as an index cancer, although not significant with a Bonferroni correction. From 1975\u20132012, incidence of breast cancer as a first cancer increased at an annual percentage change of 1.3% while breast cancer as a SPC increased at 4.7% (both p values\u2009&amp;lt;\u2009.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Male breast cancer as a SPC has increased markedly over 4 decades. Men with a history of lymphoma may experience higher-than-expected rates of breast SPC. These observations warrant further research, and suggest possible etiologic connections with disease biology, prior therapy, or genetics.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2016-0460","type":"journal-article","created":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T09:00:59Z","timestamp":1495443659000},"page":"895-900","source":"Crossref","is-referenced-by-count":7,"title":["Male Breast Cancer as a Second Primary Cancer: Increased Risk Following Lymphoma"],"prefix":"10.1093","volume":"22","author":[{"given":"Deborah E.","family":"Farr","sequence":"first","affiliation":[{"name":"Division of Surgical Oncology UT Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Wake Forest School of Medicine Wake Forest University, Winston-Salem, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema Ahsan","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Surgery Feinberg School of Medicine of Northwestern University, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary C.","family":"Schroeder","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science, College of Pharmacy University of Iowa, Iowa City, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,5,9]]},"reference":[{"key":"2021122508140745300_onco12148-bib-0001","first-page":"S147","article-title":"How to treat male breast cancer","author":"Czene","year":"2007","journal-title":"Breast"},{"key":"2021122508140745300_onco12148-bib-0002","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(06)68226-3","article-title":"Male breast cancer","volume":"367","author":"Fentiman","year":"2006","journal-title":"Lancet"},{"key":"2021122508140745300_onco12148-bib-0003","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cncr.20312","article-title":"Breast carcinoma in men: A population-based study","volume":"101","author":"Giordano","year":"2004","journal-title":"Cancer"},{"key":"2021122508140745300_onco12148-bib-0004","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1477-7819-6-58","article-title":"Male breast cancer: Is the scenario changing","volume":"6","author":"Contractor","year":"2008","journal-title":"World J Surg Oncol"},{"key":"2021122508140745300_onco12148-bib-0005","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0002-9610(97)89592-X","article-title":"A comparison outcome of male breast cancer with female breast cancer","volume":"173","author":"Willsher","year":"1997","journal-title":"Am J Surg"},{"key":"2021122508140745300_onco12148-bib-0006","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s002280050130","article-title":"Bioequivalence study of two enalapril maleate tablet formulations in healthy male volunteers. Pharmacokinetic versus pharmacodynamic approach","volume":"50","author":"Ribeiro","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"key":"2021122508140745300_onco12148-bib-0007","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/(SICI)1097-0142(19960201)77:3<490::AID-CNCR10>3.0.CO;2-#","article-title":"Male breast carcinoma: An evaluation of prognostic factors contributing to a poorer outcome","volume":"77","author":"Joshi","year":"1996","journal-title":"Cancer"},{"key":"2021122508140745300_onco12148-bib-0008","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3892\/or_00000962","article-title":"Male breast cancer: Risk factors, diagnosis, and management (Review)","volume":"24","author":"Johansen Taber","year":"2010","journal-title":"Oncol Rep"},{"key":"2021122508140745300_onco12148-bib-0009","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/jnci\/94.17.1330","article-title":"Risk of subsequent cancer following breast cancer in men","volume":"94","author":"Auvinen","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"2021122508140745300_onco12148-bib-0010","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for hodgkin's lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122508140745300_onco12148-bib-0011","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2011.38.8835","article-title":"Breast cancer risk after supradiaphragmatic radiotherapy for hodgkin's lymphoma in england and wales: A national cohort study","volume":"30","author":"Swerdlow","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122508140745300_onco12148-bib-0012","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/S0960-9776(11)70304-6","article-title":"Local therapy for breast cancer in malignant lymphoma survivors","volume":"20","author":"Intra","year":"2011","journal-title":"Breast"},{"key":"2021122508140745300_onco12148-bib-0013","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/asheducation-2011.1.323","article-title":"Late effects in the era of modern therapy for hodgkin lymphoma","volume":"2011","author":"Hodgson","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2021122508140745300_onco12148-bib-0014","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ijrobp.2013.02.007","article-title":"Patterns of failure in advanced stage diffuse large b-cell lymphoma patients after complete response to r-chop immunochemotherapy and the emerging role of consolidative radiation therapy","volume":"86","author":"Shi","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122508140745300_onco12148-bib-0015","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/annonc\/mdq389","article-title":"The impact of radiation therapy in patients with diffuse large b-cell lymphoma with positive post-chemotherapy fdg-pet or gallium-67 scans","volume":"22","author":"Dorth","year":"2011","journal-title":"Ann Oncol"},{"key":"2021122508140745300_onco12148-bib-0016","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.ijrobp.2011.12.067","article-title":"Impact of consolidation radiation therapy in stage iii-iv diffuse large b-cell lymphoma with negative post-chemotherapy radiologic imaging","volume":"84","author":"Dorth","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122508140745300_onco12148-bib-0017","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/leu.2016.113","article-title":"Effect of first-line treatment on second primary malignancies and richter's transformation in patients with cll","volume":"30","author":"Maurer","year":"2016","journal-title":"Leukemia"},{"key":"2021122508140745300_onco12148-bib-0018","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood.V98.6.1979","article-title":"Solid tumors after chronic lymphocytic leukemia","volume":"98","author":"Hisada","year":"2001","journal-title":"Blood"},{"key":"2021122508140745300_onco12148-bib-0019","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1053\/j.seminoncol.2005.12.013","article-title":"Infectious complications of chronic lymphocytic leukemia","volume":"33","author":"Wadhwa","year":"2006","journal-title":"Semin Oncol"},{"key":"2021122508140745300_onco12148-bib-0020","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00262-005-0015-8","article-title":"Immune defects in patients with chronic lymphocytic leukemia","volume":"55","author":"Ravandi","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"2021122508140745300_onco12148-bib-0021","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clim.2006.08.009","article-title":"B cell reconstitution after rituximab treatment of lymphoma recapitulates b cell ontogeny","volume":"122","author":"Anolik","year":"2007","journal-title":"Clin Immunol"},{"key":"2021122508140745300_onco12148-bib-0022","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00262-011-1168-2","article-title":"Rituximab-induced direct inhibition of t-cell activation","volume":"61","author":"Stroopinsky","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"2021122508140745300_onco12148-bib-0023","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2014.60.2094","article-title":"Risk factors for melanoma among survivors of non-hodgkin lymphoma","volume":"33","author":"Lam","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122508140745300_onco12148-bib-0024","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 who classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2016-0460","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2016-0460","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/8\/895\/41914023\/oncolo_22_8_895.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/8\/895\/41914023\/oncolo_22_8_895.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T08:15:15Z","timestamp":1640420115000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/22\/8\/895\/6444409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,9]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,5,9]]},"published-print":{"date-parts":[[2017,8,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2016-0460","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,8,1]]},"published":{"date-parts":[[2017,5,9]]}}}